Pfizer (NYSE:PFE) Trading Down 1.3% – Should You Sell?

Pfizer Inc. (NYSE:PFE)’s share price dropped 1.3% during mid-day trading on Tuesday . The stock traded as low as $24.69 and last traded at $24.75. 81,903,066 shares traded hands during trading, an increase of 97% from the average session volume of 41,572,313 shares. The stock had previously closed at $25.08.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Negative Sentiment: Pfizer’s late-stage lung cancer drug sigvotatug vedotin failed to significantly improve overall survival in the Phase 3 SigVie-002 study, disappointing investors and raising questions about the commercial value of the Seagen-acquired asset. Pfizer (PFE) Lung Cancer Drug Misses Survival Goal In Phase 3 Trial
• Negative Sentiment: Reuters also reported the experimental lung cancer treatment missed the main goal of the trial, reinforcing the negative read-through for Pfizer’s pipeline and near-term sentiment. Pfizer’s experimental drug misses main goal of lung cancer trial
• Neutral Sentiment: Pfizer highlighted that a subgroup of patients showed more favorable survival trends and that the drug had a manageable safety profile, which may soften the blow but does not change the fact that the main efficacy bar was missed. Pfizer’s Mixed Phase III Data for Sigvotatug Vedotin in NSCLC
• Neutral Sentiment: Separately, commentary about Pfizer’s obesity pipeline suggests the company could have future growth optionality, but that thesis is longer dated and is not offsetting today’s trial disappointment. Forget Novo Nordisk. Pfizer’s Obesity Pipeline Is Coming, and It Pays You 6.8% While You Wait

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Citigroup increased their price target on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, April 29th. Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a report on Monday, March 2nd. UBS Group reiterated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research report on Wednesday, May 27th. HSBC increased their target price on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. Finally, CICC Research initiated coverage on Pfizer in a research note on Thursday, April 16th. They set an “outperform” rating and a $33.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $28.82.

Pfizer Trading Down 1.3%

The stock has a market capitalization of $141.06 billion, a P/E ratio of 18.89 and a beta of 0.34. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The stock’s fifty day moving average price is $26.18 and its two-hundred day moving average price is $26.33.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 12th. Stockholders of record on Friday, May 8th were paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. The ex-dividend date of this dividend was Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Institutional Investors Weigh In On Pfizer

A number of hedge funds and other institutional investors have recently modified their holdings of PFE. Norges Bank bought a new position in Pfizer during the 4th quarter worth approximately $1,830,986,000. Morgan Stanley increased its stake in Pfizer by 19.2% in the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after purchasing an additional 14,342,946 shares during the period. Bank of New York Mellon Corp lifted its position in Pfizer by 38.9% in the fourth quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company’s stock valued at $1,208,023,000 after purchasing an additional 13,581,757 shares during the last quarter. Franklin Resources Inc. lifted its position in Pfizer by 47.8% in the third quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock valued at $638,787,000 after purchasing an additional 8,108,887 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its stake in shares of Pfizer by 577.5% during the fourth quarter. Janus Henderson Group PLC now owns 8,786,084 shares of the biopharmaceutical company’s stock valued at $218,817,000 after purchasing an additional 7,489,189 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.